Imagine having a digital crash-test dummy, but for a human heart. Instead of testing a new drug or pacemaker on a few people, this tool creates thousands of virtual patients based on real medical data. It lets doctors and engineers see if a treatment works safely across many different body types before any real person is involved.
Traditional clinical trials are slow, expensive, and carry ethical risks. They often fail to account for diverse genetic variations, leading to late-stage failures in drug and device development.
The ELVIS/V.HEART platform, consisting of a cloud-based WebApp, a Virtual Population Generator, and the Alya Red high-fidelity simulation engine.
If you are a drug development firm dealing with high failure rates in cardiotoxicity tests — this project developed the V.HEART platform that computes thousands of scenarios to assess the cardiac safety of proprietary compounds.
If you are a cardiac implant manufacturer dealing with expensive and slow clinical trials for pacemakers — this project developed a simulation engine that tests leadless pacing and cardiac pumps on digital avatars.
If you are a cardiology clinic dealing with unpredictable patient responses to therapy — this project developed digital twins of patients to act as predictive tools for personalized treatment.
Based on available project data, specific pricing is not disclosed, but the platform is deployed on commercial cloud infrastructure for customer use.
Yes, the system uses supercomputers and commercial cloud infrastructure to perform massive in-silico trials on populations of digital avatars.
The project utilizes a patented virtual population technology to generate its digital avatars.
It integrates via a WebApp with a frontend and backend system, allowing users to migrate internal cardiotoxicity study results for direct analysis.
The project period runs from 2023-03-01 to 2025-08-31, with the first version of V.HEART already deployed on the cloud.
The project is led by a single Spanish SME, ELEM BIOTECH SL, representing a 100% industry ratio. This lean structure suggests a highly focused commercial drive, as the coordinator is the sole entity responsible for the development and deployment of the V.HEART platform.
Contact ELEM BIOTECH SL in Spain regarding V.HEART cloud access.
Contact us to explore licensing opportunities for virtual population technology.
